TP53 and lung cancer: Indeed, we showed that newly identified molecular cross-talk between EphA5-mediated pathways and p53 controls the terminal fate of cells exposed to IR: in the absence of EphA5, p53-proficient lung cancer cells become senescent, and in the absence of both EphA5 and p53, lung cancer cells die.